$811 Million is the total value of Rhenman & Partners Asset Management AB's 92 reported holdings in Q1 2018. The portfolio turnover from Q4 2017 to Q1 2018 was 22.1% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| HZNP | Buy | Horizon Pharma Plc | $28,502,000 | -0.1% | 2,007,212 | +2.7% | 3.51% | -8.9% |
| CELG | Buy | Celgene Corp | $26,443,000 | +57.0% | 296,412 | +83.6% | 3.26% | +43.2% |
| ALXN | Buy | Alexion Pharmaceuticals Inc | $24,729,000 | +36.2% | 221,863 | +46.1% | 3.05% | +24.2% |
| VRTX | Sell | Vertex Pharmaceuticals Inc | $24,447,000 | +7.2% | 150,000 | -1.4% | 3.01% | -2.2% |
| JAZZ | Buy | Jazz Pharmaceuticals Plc | $22,412,000 | +24.7% | 148,436 | +11.2% | 2.76% | +13.8% |
| ABMD | Sell | Abiomed Inc | $22,258,000 | +37.3% | 76,490 | -11.6% | 2.74% | +25.3% |
| BMY | Buy | Bristol Myers Squibb Co | $22,138,000 | +178.3% | 350,000 | +169.6% | 2.73% | +153.9% |
| NKTR | Sell | Nektar Therapeutics | $22,044,000 | +4.4% | 207,458 | -41.3% | 2.72% | -4.8% |
| EXEL | Buy | Exelixis Inc | $21,845,000 | -5.0% | 986,214 | +30.4% | 2.69% | -13.3% |
| ABBV | Buy | AbbVie Inc | $19,564,000 | +29.1% | 206,700 | +31.9% | 2.41% | +17.8% |
| CI | Buy | Cigna Corp | $18,518,000 | +100.8% | 110,400 | +143.2% | 2.28% | +83.2% |
| HUM | Buy | Humana Inc | $18,280,000 | +27.1% | 68,000 | +17.2% | 2.25% | +15.9% |
| GILD | Sell | Gilead Sciences Inc | $17,869,000 | -12.7% | 237,027 | -17.1% | 2.20% | -20.4% |
| ESPR | Sell | Esperion Therapeutics Inc | $17,688,000 | -30.5% | 244,540 | -36.8% | 2.18% | -36.6% |
| UNH | Buy | United Health Group Inc | $17,334,000 | +4.1% | 81,000 | +7.3% | 2.14% | -5.0% |
| LLY | Buy | Eli Lilly & Co | $17,243,000 | +42.9% | 222,859 | +56.0% | 2.12% | +30.4% |
| MDT | Buy | Medtronic Plc Reg | $16,949,000 | +27.8% | 211,283 | +28.7% | 2.09% | +16.6% |
| ITCI | Sell | Intra-Cellular Therapies Inc | $16,687,000 | +6.3% | 792,730 | -26.9% | 2.06% | -3.1% |
| BMRN | Buy | BioMarin Pharmaceutical Inc | $16,607,000 | +33.2% | 204,849 | +46.5% | 2.05% | +21.5% |
| BDX | New | Becton Dickinson & Co | $16,253,000 | – | 75,000 | +100.0% | 2.00% | – |
| IOVA | Iovance Biotherapeutics Inc Reg | $15,957,000 | +111.3% | 944,185 | 0.0% | 1.97% | +92.7% | |
| CVS | New | CVS Health Corp | $15,793,000 | – | 253,868 | +100.0% | 1.95% | – |
| GKOS | Sell | Glaukos Corp | $15,520,000 | -0.5% | 503,400 | -17.3% | 1.91% | -9.3% |
| SAGE | Sell | Sage Therapeutics Inc | $15,302,000 | -11.5% | 95,000 | -9.5% | 1.89% | -19.2% |
| ESRX | Sell | Express Scripts Hg Co | $14,852,000 | -10.2% | 215,000 | -2.9% | 1.83% | -18.0% |
| ANTM | Buy | Anthem Inc | $13,402,000 | +92.1% | 61,000 | +96.8% | 1.65% | +75.4% |
| INCY | Sell | Incyte Corp Ltd | $13,246,000 | -14.6% | 158,963 | -2.9% | 1.63% | -22.1% |
| ABT | Buy | Abbott Laboratories | $12,104,000 | +73.8% | 202,000 | +65.6% | 1.49% | +58.6% |
| REGN | Buy | Regeneron Pharmaceuticals Inc | $11,708,000 | -0.0% | 34,000 | +9.1% | 1.44% | -8.8% |
| EW | Buy | Edwards Lifesciences Corp | $11,631,000 | +40.7% | 83,364 | +13.6% | 1.43% | +28.4% |
| BIIB | Buy | Biogen Inc | $11,583,000 | +137.6% | 42,300 | +176.5% | 1.43% | +116.7% |
| ARRY | Buy | Array BioPharma Inc | $11,448,000 | +77.8% | 701,470 | +39.4% | 1.41% | +62.2% |
| ARNA | Sell | Arena Pharmaceuticals Inc Reg | $11,283,000 | -13.9% | 285,642 | -25.9% | 1.39% | -21.4% |
| AGN | Buy | Allergan Plc | $10,097,000 | +4.5% | 60,000 | +1.6% | 1.24% | -4.6% |
| ALNY | Buy | Alnylam Pharmaceuticals Inc | $10,000,000 | +33.5% | 83,967 | +42.4% | 1.23% | +21.8% |
| BSX | Boston Scientific Corp | $9,506,000 | +10.2% | 347,968 | 0.0% | 1.17% | +0.5% | |
| NVCR | Sell | NovoCure Ltd Reg | $9,483,000 | +0.4% | 435,000 | -7.0% | 1.17% | -8.4% |
| NBIX | Sell | Neurocrine Biosciences Inc | $9,122,000 | -0.3% | 110,000 | -6.8% | 1.12% | -9.1% |
| XNCR | Sell | Xencor Inc | $8,994,000 | +29.2% | 300,000 | -5.5% | 1.11% | +18.0% |
| ABC | Sell | AmerisourceBergen Corp | $8,988,000 | -43.8% | 104,261 | -40.2% | 1.11% | -48.8% |
| PTLA | Buy | Portola Pharmaceuticals Inc | $8,826,000 | -14.1% | 270,248 | +28.0% | 1.09% | -21.7% |
| LOXO | Sell | Loxo Oncology Inc | $8,653,000 | +13.9% | 75,000 | -16.9% | 1.07% | +3.9% |
| MYOK | Sell | MyoKardia Inc Reg | $8,212,000 | +9.4% | 168,272 | -5.6% | 1.01% | -0.2% |
| FGEN | FibroGen Inc | $7,833,000 | -2.5% | 169,547 | 0.0% | 0.97% | -11.0% | |
| AGIO | Sell | Agios Pharmaceuticals Inc | $7,769,000 | +35.9% | 95,000 | -5.0% | 0.96% | +24.1% |
| MGNX | Sell | Macrogenics Inc | $7,548,000 | +28.7% | 300,000 | -2.8% | 0.93% | +17.4% |
| CNC | Buy | Centene Corp | $6,947,000 | +53.0% | 65,000 | +44.4% | 0.86% | +39.6% |
| SGEN | New | Seattle Genetics Inc Reg | $6,804,000 | – | 130,000 | +100.0% | 0.84% | – |
| RVNC | Buy | Revance Therapeutics Inc | $6,258,000 | -4.1% | 203,181 | +11.3% | 0.77% | -12.6% |
| IMMU | Sell | Immunomedics Inc | $6,068,000 | -21.8% | 415,330 | -13.5% | 0.75% | -28.7% |
| ACAD | Sell | Acadia Pharmaceuticals Inc | $6,067,000 | -40.5% | 270,000 | -20.3% | 0.75% | -45.8% |
| RIGL | Sell | Rigel Pharmaceuticals Inc | $5,727,000 | -23.6% | 1,617,769 | -16.3% | 0.71% | -30.3% |
| FLXN | Sell | Flexion Therapeutics Inc | $5,304,000 | -19.1% | 236,686 | -9.6% | 0.65% | -26.1% |
| ALKS | Buy | Alkermes Plc | $5,263,000 | +63.5% | 90,800 | +54.4% | 0.65% | +49.2% |
| ADMS | Sell | Adamas Pharmaceuticals Inc | $5,010,000 | -78.7% | 209,644 | -69.7% | 0.62% | -80.5% |
| WBA | Buy | Walgreens Boots Alliance Inc | $4,910,000 | +2.9% | 75,000 | +14.2% | 0.60% | -6.2% |
| SGMO | Sangamo Therapeutics Inc Reg | $4,860,000 | +15.9% | 255,793 | 0.0% | 0.60% | +5.6% | |
| ONCE | Sell | Spark Therapeutics Inc | $4,501,000 | +24.7% | 67,600 | -3.7% | 0.56% | +13.7% |
| New | Livanova Plc | $4,425,000 | – | 50,000 | +100.0% | 0.54% | – | |
| CHRS | Coherus BioSciences Inc | $3,868,000 | +25.6% | 350,000 | 0.0% | 0.48% | +14.7% | |
| ELGX | Sell | Endologix Inc | $3,832,000 | -25.1% | 906,002 | -5.2% | 0.47% | -31.7% |
| MDCO | New | Medicines Co | $3,294,000 | – | 100,000 | +100.0% | 0.41% | – |
| EPZM | Sell | Epizyme Inc | $3,218,000 | +17.8% | 181,291 | -16.7% | 0.40% | +7.6% |
| OMCL | Omnicell Inc | $2,537,000 | -10.5% | 58,445 | 0.0% | 0.31% | -18.3% | |
| ACHN | Achillion Pharmaceuticals Inc | $2,478,000 | +28.9% | 667,800 | 0.0% | 0.30% | +17.3% | |
| AERI | Sell | Aerie Pharmaceuticals Inc | $2,170,000 | -71.4% | 40,000 | -68.5% | 0.27% | -73.9% |
| VRAY | Buy | ViewRay Inc Reg | $2,137,000 | -18.3% | 332,385 | +17.7% | 0.26% | -25.5% |
| PIRS | New | Pieris Pharmaceuticals Inc Reg | $2,046,000 | – | 300,000 | +100.0% | 0.25% | – |
| ZGNX | Sell | Zogenix Inc Reg | $2,003,000 | -3.5% | 50,000 | -3.5% | 0.25% | -11.8% |
| CMRX | Chimerix Inc | $1,778,000 | +12.3% | 342,000 | 0.0% | 0.22% | +2.3% | |
| NLNK | NewLink Genetics Corp | $1,313,000 | -10.6% | 181,047 | 0.0% | 0.16% | -18.2% | |
| KERX | Keryx Biopharmaceuticals Inc | $1,236,000 | -12.0% | 302,157 | 0.0% | 0.15% | -20.0% | |
| SNSS | Sunesis Pharmaceuticals Inc Reg | $1,224,000 | -26.3% | 450,100 | 0.0% | 0.15% | -32.6% | |
| DERM | Dermira Inc Reg | $759,000 | -71.3% | 95,000 | 0.0% | 0.09% | -73.7% | |
| ADVM | Adverum Biotechnologies Inc | $737,000 | +65.6% | 127,006 | 0.0% | 0.09% | +51.7% | |
| HAL | Buy | Halliburton Co (Hg Co) | $688,000 | +26.2% | 14,659 | +31.5% | 0.08% | +14.9% |
| XOM | Buy | Exxon Mobil Corp | $636,000 | +33.6% | 8,526 | +49.7% | 0.08% | +21.9% |
| New | Janus Henderson Group Plc Reg | $591,000 | – | 17,859 | +100.0% | 0.07% | – | |
| JPM | Buy | JPMorgan Chase & Co | $593,000 | +22.8% | 5,391 | +19.3% | 0.07% | +12.3% |
| IBM | Buy | IBM Corp | $579,000 | +113.7% | 3,773 | +113.6% | 0.07% | +91.9% |
| MSFT | Buy | Microsoft Corp | $499,000 | +21.7% | 5,465 | +14.0% | 0.06% | +12.7% |
| F | Buy | Ford Motor Co | $472,000 | +33.0% | 42,606 | +50.0% | 0.06% | +20.8% |
| CVX | New | Chevron Corp | $473,000 | – | 4,148 | +100.0% | 0.06% | – |
| DIS | New | Walt Disney Co (The) | $463,000 | – | 4,613 | +100.0% | 0.06% | – |
| BUD | Buy | Anheuser-Busch InBev SA ADR spons repr 1 Sharesponsored adr | $463,000 | +47.9% | 4,209 | +50.0% | 0.06% | +35.7% |
| QCOM | Buy | Qualcomm Inc | $446,000 | +29.7% | 8,052 | +50.0% | 0.06% | +19.6% |
| STAA | Sell | Staar Surgical Co | $365,000 | -69.1% | 24,658 | -67.7% | 0.04% | -71.9% |
| SYMC | Buy | Symantec Corp | $363,000 | +38.0% | 14,039 | +50.0% | 0.04% | +25.0% |
| RGLS | Regulus Therapeutic Inc | $354,000 | -31.0% | 492,878 | 0.0% | 0.04% | -36.2% | |
| WFC | Sell | Wells Fargo & Co | $307,000 | -33.7% | 5,858 | -23.3% | 0.04% | -39.7% |
| PFE | Sell | Pfizer Inc | $311,000 | -17.5% | 8,754 | -16.0% | 0.04% | -25.5% |
| RARX | Sell | Ra Pharmaceuticals Inc Reg | $208,000 | -77.4% | 39,115 | -63.9% | 0.03% | -79.2% |
| JHG | Exit | Janus Henderson Group Plc Reg | $0 | – | -11,906 | -100.0% | -0.06% | – |
| TTPH | Exit | Tetraphase Pharmaceuticals Inc | $0 | – | -160,908 | -100.0% | -0.14% | – |
| NVRO | Exit | Nevro Corp | $0 | – | -15,145 | -100.0% | -0.14% | – |
| ICPT | Exit | Intercept Pharmaceuticals Inc | $0 | – | -38,500 | -100.0% | -0.30% | – |
| DXCM | Exit | Dexcom Inc | $0 | – | -70,625 | -100.0% | -0.55% | – |
| LIVN | Exit | Livanova Plc | $0 | – | -53,000 | -100.0% | -0.57% | – |
| RARE | Exit | Ultragenyx Pharmaceutical Inc | $0 | – | -95,000 | -100.0% | -0.60% | – |
| DVAX | Exit | Dynavax Technologies Corp | $0 | – | -242,812 | -100.0% | -0.61% | – |
| PBYI | Exit | Puma Biotechnology Inc | $0 | – | -50,000 | -100.0% | -0.67% | – |
| JUNO | Exit | Juno Therapeutics Inc | $0 | – | -109,430 | -100.0% | -0.68% | – |
| HCA | Exit | HCA Healthcare Inc | $0 | – | -58,886 | -100.0% | -0.70% | – |
| UHS | Exit | Universal Health Services Inc Bcl b | $0 | – | -52,433 | -100.0% | -0.80% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2018-04-11
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| UNITEDHEALTH GROUP INC | 40 | Q3 2023 | 4.0% |
| BIOMARIN PHARMACEUTICAL INC | 40 | Q3 2023 | 5.0% |
| ALKERMES PLC | 40 | Q3 2023 | 3.3% |
| LILLY ELI & CO | 39 | Q3 2023 | 5.8% |
| CVS HEALTH CORP | 39 | Q3 2023 | 3.5% |
| INTRA-CELLULAR THERAPIES INC | 39 | Q3 2023 | 2.4% |
| EDWARDS LIFESCIENCES CORP | 39 | Q3 2023 | 1.7% |
| VERTEX PHARMACEUTICALS INC | 38 | Q3 2023 | 4.3% |
| REVANCE THERAPEUTICS INC | 38 | Q3 2023 | 0.9% |
| ABBVIE INC | 37 | Q3 2023 | 4.4% |
View Rhenman & Partners Asset Management AB's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-13 |
| 13F-HR/A | 2023-11-13 |
| 13F-HR | 2023-11-09 |
| 13F-HR | 2023-08-11 |
| 13F-HR | 2023-05-12 |
| 13F-HR | 2023-02-13 |
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-12 |
| 13F-HR | 2022-05-13 |
| 13F-HR | 2022-02-11 |
View Rhenman & Partners Asset Management AB's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.